Pelthos Therapeutics agrees to merge with Castle Creek Biosciences

• Castle Creek Biosciences will merge with Pelthos Therapeutics, adding late-stage skin disease gene therapy candidate D-Fi to its dermatology portfolio.
• Castle Creek stockholders will receive 5,200,000 common shares at closing, representing approximately 32.5% of fully diluted shares.
• D-Fi FDA approval could trigger up to 5,800,000 additional common shares; sellers also qualify for 80% of any priority review voucher sale proceeds.
• Milestone payments total up to $300 million: $50 million for specified Phase 3 endpoints, up to $250 million tied to commercialization and sales.
• Closing is expected by the end of the first quarter of 2027, subject to customary conditions, including Castle Creek stockholder approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300909PRIMZONEFULLFEED9856900) on October 30, 2026, and is solely responsible for the information contained therein.